Neurocrine Biosciences
NBIX
NBIX
689 hedge funds and large institutions have $13.1B invested in Neurocrine Biosciences in 2026 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 297 increasing their positions, 215 reducing their positions, and 111 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
24% less first-time investments, than exits
New positions opened: 84 | Existing positions closed: 111
43% less call options, than puts
Call options by funds: $39.1M | Put options by funds: $69M
Holders
689
Holding in Top 10
8
Calls
$39.1M
Puts
$69M
Top Buyers
| 1 | +$275M | |
| 2 | +$221M | |
| 3 | +$166M | |
| 4 |
Millennium Management
New York
|
+$107M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$80.5M |
Top Sellers
| 1 | -$228M | |
| 2 | -$225M | |
| 3 | -$152M | |
| 4 |
DM
Deerfield Management
New York
|
-$76.2M |
| 5 |
ZIG
Zurich Insurance Group
Zurich,
Switzerland
|
-$65.2M |
